Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) has reported second-quarter 2026 net product revenue of approximately $13.5 million, a significant increase from $2 million in the same period last year. The surge is primarily attributed to $11 million in net sales of TONMYA, its recently approved fibromyalgia treatment. TONMYA recorded 12,592 total prescriptions during the quarter, a 100% sequential increase, with new patient prescriptions up 36% and refills rising 207%.
The company announced that TONMYA currently has coverage representing approximately 136 million lives across commercial, managed Medicare, and Medicaid channels. This coverage is expected to expand to approximately 145 million lives when a managed Medicare agreement takes effect on Jan. 1, 2027. This broader access is likely to enhance patient reach and drive further prescription growth, positioning TONMYA as a key player in the fibromyalgia market.
Beyond commercial success, Tonix continues to advance its clinical pipeline. The company has enrolled the first patient in the potentially pivotal Phase 2 HORIZON study of TNX-102 SL for major depressive disorder. Additionally, it is preparing to begin an adaptive Phase 2 field study of TNX-4800 for Lyme disease prevention in the first quarter of 2027, pending final FDA review and agreement on the protocol. These developments underscore Tonix's commitment to addressing high unmet medical needs in CNS and immunology.
Financially, Tonix ended the quarter with approximately $176.2 million in cash and cash equivalents. The company stated that these resources, along with third-quarter equity proceeds to date, are expected to fund planned operations and capital expenditures into early second-quarter 2027. This financial runway provides stability as the company scales TONMYA and progresses its pipeline.
The strong Q2 performance and pipeline advancements are critical for stakeholders. For patients, TONMYA offers a new treatment option for fibromyalgia, a condition that has seen limited innovation in over 15 years. For investors, the revenue growth and expanding coverage signal commercial viability, while the pipeline holds potential for future value creation. The progression of TNX-102 SL and TNX-4800 could address major depressive disorder and Lyme disease, respectively, broadening the company's therapeutic impact.
For more information, visit the full press release at https://nnw.fm/6Yytj and the company's newsroom at https://nnw.fm/TNXP.
